









Markets
/
Stocks
/
nasdaq-phge
/

Biomx Inc

PHGE

0.536USD

+0.027+5.35%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

14.17MMarket Cap

LossP/E TTM



Biomx Inc

0.536

+0.027+5.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

258 / 506

Overall Ranking

417 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

15.500

Target Price

+2946.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Undervalued

The company’s latest PE is -17.08, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 19.36M shares, increasing 24.24% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.96.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -16.21, which is -97.81% below the recent high of -0.36 and 96.48% above the recent low of -0.57.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 258/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Biomx Inc is 15.50, with a high of 16.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

15.500

Target Price

+2946.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Biomx Inc

PHGE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.43, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.57 and the support level at 0.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.43

Change

0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.003

Neutral

RSI(14)

55.514

Neutral

STOCH(KDJ)(9,3,3)

81.830

Buy

ATR(14)

0.033

High Vlolatility

CCI(14)

93.353

Neutral

Williams %R

21.987

Buy

TRIX(12,20)

-0.178

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.501

Buy

MA10

0.494

Buy

MA20

0.517

Buy

MA50

0.487

Buy

MA100

0.492

Buy

MA200

0.587

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Deerfield Management Company, L.P.

2.49M

+100.00%

Cystic Fibrosis Foundation

2.49M

+39.51%

Nantahala Capital Management, LLC

2.49M

+44.07%

AIGH Capital Management, LLC.

1.18M

+82.04%

Centaurus Investments Limited

1.07M

Ikarian Capital LLC

892.98K

AMR Action Fund LP

876.89K

+187.05%

Telmina Ltd

560.27K

+97.30%

Nimble Ventures LLC

510.20K

+0.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.